Rivaroxaban in patients with a recent acute coronary syndrome.

By J. Mega, E. Braunwald, S. Wiviott, J. Bassand, Deepak L. Bhatt, C. Bode, P. Burton, Marc Cohen, N. Cook-Bruns, K. Fox and 7 more. New England Journal of Medicine, 2012

1,841 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology

View Paper: https://www.semanticscholar.org/paper/837e203df3270dc05004e4caa948cfb1e0d2f509

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. M. Ezekowitz
2. Sonia S Anand
3. Stanley Nattel
4. Hani Jneid
5. Allan S. Jaffe
6. Gerhard Hindricks

Citations in the corpus

• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “Mega 2012 (180) 22077192 N/A Double-blind, PC-controlled trial N=15,526 pts bidbid doses of either 2.”
• 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation (2017, background): “First, a direct thrombin or Factor Xa inhibitor can be administered several hours following ablation.(826,827,853,854) Second, low molecular weight heparin (enoxaparin 0.”
• Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. (2018, positive): “…venous thromboembolism after orthopaedic surgery, 15 and the Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-2) trial 16 showed that low-dose rivaroxaban (2·5 mg twice a day) used in addition to dual antiplatelet therapy reduced major adverse cardiovascular events in…”